Association Between Plasminogen Activator Inhibitor-1-675 4G/5G Insertion/Deletion Polymorphism and Chronic Obstructive Pulmonary Disease

COPD. 2016 Dec;13(6):756-759. doi: 10.3109/15412555.2016.1168392. Epub 2016 Apr 13.

Abstract

Molecular pathology of chronic obstructive pulmonary disease (COPD) is still being investigated to discover relationships with disease pathogenesis. Evidence of plasminogen activator inhibitor-1 (PAI-1) overexpression in the sputum and the blood of COPD patients is growing. We aimed to investigate the potential relation between PAI-1 promoter 4G/5G insertion/deletion polymorphism and COPD development. In a case-control study, we genotyped 117 COPD patients and 160 control subjects for PAI-1 promoter 4G/5G polymorphism by an allele-specific polymerase chain reaction analysis. All subjects were male smokers. In the co-dominant model, there was a significant difference in the distribution of 5G/5G, 4G/5G and 4G/4G genotypes between COPD patients and controls (p = 0.002). In the recessive model, carriers of 4G/4G genotype were significantly higher in COPD patients than controls (p = 0.01). Carriers of 4G/4G genotype were at higher risk to develop COPD than those carrying 5G/5G or 4G/5G genotypes (crude odds ratio (OR) = 2.10, 95% confidence interval (CI) = 1.19-3.73, adjusted OR = 2.5, 95% CI = 1.22-3.99). In conclusion, PAI-1 4G/5G genetic variations are associated with COPD development in males.

Keywords: Association; COPD; PAI-1 4G/5G.

MeSH terms

  • Adult
  • Aged
  • Case-Control Studies
  • Genes, Dominant
  • Genes, Recessive
  • Genotype
  • Humans
  • INDEL Mutation
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Polymorphism, Genetic
  • Promoter Regions, Genetic
  • Pulmonary Disease, Chronic Obstructive / genetics*
  • Smoking

Substances

  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human